Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published online before print January 14, 2008, 10.1148/radiol.2463070077
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2463070077v1
246/3/926    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Hagiwara, M.
Right arrow Articles by Taouli, B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hagiwara, M.
Right arrow Articles by Taouli, B.
(Radiology 2008;246:926-934.)
© RSNA, 2008


Technical Developments

Advanced Liver Fibrosis: Diagnosis with 3D Whole-Liver Perfusion MR Imaging—Initial Experience1

Mari Hagiwara, MD, Henry Rusinek, PhD, Vivian S. Lee, MD, PhD, Mariela Losada, MD, Michael A. Bannan, MD, Glenn A. Krinsky, MD 2, and Bachir Taouli, MD

1 From the Departments of Radiology (M.H., H.R., V.S.L., G.A.K., B.T.) and Pathology (M.L., M.A.B.), New York University Medical Center, 560 First Ave, New York, NY 10016. Received January 12, 2007; revision requested March 15; revision received May 15; accepted June 13; final version accepted September 7. Address correspondence to B.T. (e-mail: bachir.taouli{at}med.nyu.edu).

Institutional review board approval and informed consent were obtained for this HIPAA–compliant study. The purpose of this study was to prospectively evaluate sensitivity and specificity of various estimated perfusion parameters at three-dimensional (3D) perfusion magnetic resonance (MR) imaging of the liver in the diagnosis of advanced liver fibrosis (stage ≥ 3), with histologic analysis, liver function tests, or MR imaging as the reference standard. Whole-liver 3D perfusion MR imaging was performed in 27 patients (17 men, 10 women; mean age, 55 years) after dynamic injection of 8–10 mL of gadopentetate dimeglumine. The following estimated perfusion parameters were measured with a dual-input single-compartment model: absolute arterial blood flow (Fa), absolute portal venous blood flow (Fp), absolute total liver blood flow (Ft) (Ft = Fa + Fp), arterial fraction (ART), portal venous fraction (PV), distribution volume (DV), and mean transit time (MTT) of gadopentetate dimeglumine. Patients were assigned to two groups (those with fibrosis stage ≤ 2 and those with fibrosis stage ≥ 3), and the nonparametric Mann-Whitney test was used to compare Fa, Fp, Ft, ART, PV, DV, and MTT between groups. Receiver operating characteristic curve analysis was used to assess the utility of perfusion estimates as predictors of advanced liver fibrosis. There were significant differences for all perfusion MR imaging–estimated parameters except Fp and Ft. There was an increase in Fa, ART, DV, and MTT and a decrease in PV in patients with advanced fibrosis compared with those without advanced fibrosis. DV had the best performance, with an area under the receiver operating characteristic curve of 0.824, a sensitivity of 76.9% (95% confidence interval: 46.2%, 94.7%), and a specificity of 78.5% (95% confidence interval: 49.2%, 95.1%) in the prediction of advanced fibrosis.

© RSNA, 2008







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 2008 by the Radiological Society of North America.